Leveraging manufacturing expertise to overcome key challenges attributed to commercial-scale cell therapies.
PLAY VIDEO ABOVE * Catalent, the sponsor of this content would like to send you information about their products and services. If you do not wish to receive these emails, click here to opt out.
Cell and gene therapies constitute a dynamic market with unprecedented growth. As new therapeutics are entering the market with double digit growth, existing therapies are also moving through late-stage clinical phases.
Capacity constraints, especially in viral vector manufacturing, can impact the downstream supply chain tied to gene-enabled cell therapies. This highlights the importance of partnering with manufacturers who possess integrated capabilities across the full value chain along with early to late stage capacity to allow therapeutic programs to evolve efficiently.
For this webinar, hosted in partnership with Catalent, join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.
WHAT TO EXPECT
This 60-minute session will feature a short presentation with a session dedicated to an interactive panel discussion where you will be able to ask your questions.
Key topics for discussion will include:
• Effective partnering and full supply chain acceleration
How working with an integrated partner that can support manufacturing – from plasmid DNA to clinical supply – can facilitate faster transition of the full value chain for gene-enabled cell therapies
• Managing volume of programs through expertise
How outsourcing partners leverage expertise from experience managing multiple clients, optimizing critical quality and manufacturing attributes
• Handling quality and regulatory questions
Where the key regulatory questions may be in early vs late-stage gene-enabled cell therapy programs, what expertise is required to overcome them, and how best to approach them
This webinar was produced in partnership with Catalent.